Generic Name and Formulations:
Sebelipase alfa 20mg/10mL; soln for IV infusion after dilution; preservative-free.
Alexion Pharmaceuticals, Inc.
Indications for KANUMA:
Treatment of lysosomal acid lipase (LAL) deficiency.
Adults and Children:
<1 month: not established. Give as IV infusion over ≥2hrs; consider further prolonging infusion time for the 3mg/kg dose or if a hypersensitivity reaction occurs. May consider a 1hr infusion for the 1mg/kg dose in those who tolerate the infusion. ≥1 month: 1mg/kg once every other week. If rapidly progressive within first 6 months of life: initially 1mg/kg once weekly; increase to 3mg/kg once weekly if optimal response not achieved. May pre-treat with antipyretics and/or antihistamines.
Monitor for hypersensitivity reactions during and after infusion; interrupt or lower infusion rate based on severity. Discontinue immediately and treat if severe hypersensitivity including anaphylaxis occurs. Eggs or egg products allergy. Pregnancy. Nursing mothers.
Hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme.
Diarrhea, vomiting, fever, rhinitis, anemia, cough, nasopharyngitis, urticaria, headache, oropharyngeal pain, asthenia, constipation, nausea.
Endocrinology Advisor Articles
- Fasting Glycemic Variability Indicates Increased Risk for Type 2 Diabetes
- Heritability of BMI Stronger in Obesogenic Environments
- Domestic Refrigeration May Pose Underestimated Risk for Insulin Quality
- Sitagliptin Provides Better Glycemic Control Than Dapagliflozin in T2D With Renal Impairment
- Adverse Events Associated With Diazoxide Treatment for Congenital Hyperinsulinism
- Causes of Burnout in Resident Physicians Examined
- Thyroid Hormone Therapy Not Beneficial for Subclinical Hypothyroidism
- Bone-Derived Factors in the Treatment of Diabetes
- Bariatric Surgery Reduces Macrovascular Complications in Obesity, T2D
- Without Medicaid Expansion, Poor Patients Forgo Medical Care